Results 231 to 240 of about 5,243,668 (286)

Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma

Molecular Oncology, EarlyView.
The causes of central nervous system (CNS) hemangioblastoma in Von Hippel–Lindau (vHL) disease are unclear. We used Whole Exome Sequencing (WES) on familial hemangioblastoma to investigate events that underlie tumor development. Our findings suggest that VHL loss creates a permissive environment for tumor formation, while additional alterations ...
Maja Dembic, Anne Nørremølle, Lilian Bomme Ousager, Lars van Brakel Andersen, Marie Louise Mølgaard Binderup, Mads Thomassen   +5 more
wiley   +1 more source

Assessing the prevalence of non-use of cervical cancer screening in Khouribga, Morocco. [PDF]

Sci Rep
Hachimi SE, Essayagh F, Essayagh M, Kazadi GB, Lemriss H, Addakiri K, Zadran R, Tigaidi H, Lambaki A, Essayagh S, Essayagh T.   +10 more
europepmc   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Factors Influencing Universal Coverage of AI-Assisted Cervical Cancer Screening: Qualitative Study Based on the Macro Model of Health System.

J Med Internet Res
Ji L, Zhou X, Yao L.
europepmc   +1 more source

Equity in awareness and utilization of cervical cancer screening services among women of reproductive age in Uganda: Analysis of vertical equity using evidence from UDHS 2022. [PDF]

PLoS One
Emesu G, Kiracho EE, Jatho A, Kagaayi J, Mukose AD, Kyomuhangi A.   +5 more
europepmc   +1 more source

Modelling the time to cervical cancer elimination in England: strategies for achieving elimination by 2040. [PDF]

BMJ Public Health
Palmer C, Ovcinnikova-Hutchings O, Engelbrecht K, Favato G, Stewart A, Lalondrelle S, Chatterjee J, Ntais D, Daniels V.   +8 more
europepmc   +1 more source

Reimagining lung screening in women. [PDF]

Br J Radiol
Sandler KL.
europepmc   +1 more source